Advertisement
| aml car t therapy: The EBMT/EHA CAR-T Cell Handbook Nicolaus Kröger, John Gribben, Christian Chabannon, Ibrahim Yakoub-Agha, Hermann Einsele, 2022-02-07 This first open access European CAR-T Handbook, co-promoted by the European Society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA), covers several aspects of CAR-T cell treatments, including the underlying biology, indications, management of side-effects, access and manufacturing issues. This book, written by leading experts in the field to enhance readers’ knowledge and practice skills, provides an unparalleled overview of the CAR-T cell technology and its application in clinical care, to enhance readers’ knowledge and practice skills. |
| aml car t therapy: Chimeric Antigen Receptor T-Cell Therapies for Cancer E-Book Daniel W. Lee, Nirali N. Shah, 2019-11-30 From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance on the implementation and management of CAR T-cell therapy from Drs. Daniel W. Lee and Nirali N. Shah, this clinical resource keeps you up to date on the latest developments in this rapidly evolving area. - Covers all clinical aspects, including patient referral, toxicities management, comorbidities, bridging therapy, post-CAR monitoring, and multidisciplinary approaches to supportive care. - Includes key topics on associated toxicities such as predictive biomarkers, infections, and multidisciplinary approaches to supportive care. - Presents current knowledge on FDA approved CAR T-cell products as well as developments on the horizon. - Editors and authors represent leading investigators in academia and worldwide pioneers of CAR therapy. |
| aml car t therapy: Nonclinical Safety Assessment William J. Brock, Kenneth L. Hastings, Kathy M. McGown, 2013-04-29 Nonclinical Safety Assessment Nonclinical Safety Assessment A Guide to International Pharmaceutical Regulations Bringing a new drug to market is a costly time-consuming process. Increased regional and international regulation over the last twenty years, while necessary, has only served to amplify these costs. In response to this escalation, developmental strategies have shifted towards a more global approach. In order to create the most cost-effective and safe processes, it is critical for those bringing drugs to market to understand both the globally accepted regulations and the local variations. Nonclinical Safety Assessment: A Guide to International Pharmaceutical Regulations provides a practical description of nonclinical drug development regulations and requirements in the major market regions. It includes: ICH – the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use National regulations, including US FDA, Canada, Mercosur and Brazil, South Africa, China, Japan, India and Australia Repeated dose toxicity studies Carcinogenicity; Genotoxicity; Developmental and reproductive toxicology; Immunotoxicology Biotechnology-derived pharmaceuticals Vaccine development Phototoxicity and photocarcinogenicity Degradants, impurities, excipients and metabolites Primarily intended for those professionals actively involved in the nonclinical and clinical development of a pharmaceutical product, including toxicologists, pharmacologists, clinicians and project managers, this book provides a roadmap for successful new drug approval and marketing. |
| aml car t therapy: The EBMT Handbook Nicolaus Kröger, Mohamad Mohty, Carlo Dufour, 2020-10-08 This Open Access edition of the European Society for Blood and Marrow Transplantation (EBMT) handbook addresses the latest developments and innovations in hematopoietic stem cell transplantation and cellular therapy. Consisting of 93 chapters, it has been written by 175 leading experts in the field. Discussing all types of stem cell and bone marrow transplantation, including haplo-identical stem cell and cord blood transplantation, it also covers the indications for transplantation, the management of early and late complications as well as the new and rapidly evolving field of cellular therapies. This book provides an unparalleled description of current practices to enhance readers' knowledge and practice skills. This work was published by Saint Philip Street Press pursuant to a Creative Commons license permitting commercial use. All rights not granted by the work's license are retained by the author or authors. |
| aml car t therapy: Normal and Malignant Hematopoiesis Enrico Mihich, Donald Metcalf, 2012-12-06 ''An exciting glance at key issues in contemporary hematopoiesis.'' -The Quarterly Review of Biology |
| aml car t therapy: Allogeneic Stem Cell Transplantation Hillard M. Lazarus, Mary J. Laughlin, 2010-03-02 Since the original publication of Allogeneic Stem Cell Transplantation: Clinical Research and Practice, Allogeneic hematopoietic stem cell transplantation (HSC) has undergone several fast-paced changes. In this second edition, the editors have focused on topics relevant to evolving knowledge in the field in order to better guide clinicians in decision-making and management of their patients, as well as help lead laboratory investigators in new directions emanating from clinical observations. Some of the most respected clinicians and scientists in this discipline have responded to the recent advances in the field by providing state-of-the-art discussions addressing these topics in the second edition. The text covers the scope of human genomic variation, the methods of HLA typing and interpretation of high-resolution HLA results. Comprehensive and up-to-date, Allogeneic Stem Cell Transplantation: Clinical Research and Practice, Second Edition offers concise advice on today's best clinical practice and will be of significant benefit to all clinicians and researchers in allogeneic HSC transplantation. |
| aml car t therapy: Childhood Acute Lymphoblastic Leukemia Ajay Vora, 2017-04-21 This book provides a comprehensive and up-to-date review of all aspects of childhood Acute Lymphoblastic Leukemia, from basic biology to supportive care. It offers new insights into the genetic pre-disposition to the condition and discusses how response to early therapy and its basic biology are utilized to develop new prognostic stratification systems and target therapy. Readers will learn about current treatment and outcomes, such as immunotherapy and targeted therapy approaches. Supportive care and management of the condition in resource poor countries are also discussed in detail. This is an indispensable guide for research and laboratory scientists, pediatric hematologists as well as specialist nurses involved in the care of childhood leukemia. |
| aml car t therapy: Management of Hematologic Malignancies Susan O'Brien, Julie M. Vose, Hagop M. Kantarjian, 2010-11-18 Hematologic malignancies were the first human cancers to be studied in depth at the molecular level, and recent years have seen important advances in treatment. This comprehensive reference book covers the full range of hematologic malignancies, including all subtypes of leukemias, lymphomas, and plasma cell dyscrasias. Authored by internationally known experts, each chapter emphasizes diagnostic work-up, staging, and therapeutic approaches. Up-to-date hematopathology, treatment, and outcomes data are presented in a way which is directly applicable to patient care. Highly illustrated with color images, graphs, flowcharts and treatment algorithms, the book is perfect for quick clinical reference as well as providing detailed reference lists for further study. With its authoritative and practical focus and visually stimulating presentation, this is a key text for hematology and oncology fellows, physicians, oncology nurses, physician assistants and other healthcare workers in the field of oncology. |
| aml car t therapy: Policy Issues in the Clinical Development and Use of Immunotherapy for Cancer Treatment National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Care Services, National Cancer Policy Forum, 2016-12-10 Immunotherapy is a form of cancer therapy that harnesses the body's immune system to destroy cancer cells. In recent years, immunotherapies have been developed for several cancers, including advanced melanoma, lung cancer, and kidney cancer. In some patients with metastatic cancers who have not responded well to other treatments, immunotherapy treatment has resulted in complete and durable responses. Given these promising findings, it is hoped that continued immunotherapy research and development will produce better cancer treatments that improve patient outcomes. With this promise, however, there is also recognition that the clinical and biological landscape for immunotherapies is novel and not yet well understood. For example, adverse events with immunotherapy treatment are quite different from those experienced with other types of cancer therapy. Similarly, immunotherapy dosing, therapeutic responses, and response time lines are also markedly different from other cancer therapies. To examine these challenges and explore strategies to overcome them, the National Academies of Sciences, Engineering, and Medicine held a workshop in February and March of 2016. This report summarizes the presentations and discussions from the workshop. |
| aml car t therapy: Immunotherapies for Acute Myeloid Leukemia Jochen Greiner, 2020 The efficacy of immunotherapeutic approaches in the treatment of different cancer types is becoming increasingly obvious, and immunotherapies in cancer treatment have experienced a significant breakthrough in the last few years. Immunotherapy encompasses several diverse treatment approaches, each of which has a distinct mechanism of action, and all of which are designed to boost or restore immune function in some manner. Consequently, T cell activating immunotherapeutic approaches like immune checkpoint inhibition, chimeric antigen receptor T cells (CARs), or bi-specific T cell activating antibodies are becoming increasingly important treatment strategies in different solid tumor types as well as in hematological malignancies. T cell responses against malignant cells play a major role in maintaining remission and prolonging overall survival in patients after allogeneic stem cell transplantation and donor lymphocyte infusions (DLI) due to the graft-versus-leukemia effect. In acute myeloid leukemia (AML) after intensive chemotherapy, most patients achieve complete remission; however, the overall survival for all AML patients, especially in elderly patients, is still relatively low. Immunotherapeutic approaches for AML patients might be options to reduce the relapse rate and improve overall survival. This Special Issue will focus on immunotherapeutic approaches in AML in established therapies, like the allogeneic stem cell transplantation including new concepts improving the graft-versus-leukemia effect, but also on new efforts to improve immune responses like adoptive T cell transfer, immune checkpoint inhibition, bi-specific antibodies, and CAR-T-cell approaches. |
| aml car t therapy: Haploidentical Transplantation Stefan O. Ciurea, Rupert Handgretinger, 2018-05-03 In this book, world-renowned experts in the field express well-reasoned opinions on a range of issues and controversies relating to haploidentical transplantation with the aim of providing practicing hematologists with clinically relevant and readily applicable information. Among the areas covered are graft manipulation and methods to control T-cell alloreactivity, the nature of the ideal graft and donor, haploidentical transplantation in pediatric and adult patients with malignant and nonmalignant diseases, immunologic reconstitution following transplantation, complications, and the prevention and treatment of relapse post transplantation. Attention is drawn to the implications of high-impact clinical trials whenever such trials are available. The readily intelligible text is complemented by numerous helpful tables, algorithms, and figures. The book will provide practical support for hematologists and transplant physicians as they attempt to provide optimal care in this exciting but increasingly complex medical specialty. |
| aml car t therapy: Gene and Cellular Immunotherapy for Cancer Armin Ghobadi, John F. DiPersio, 2022-01-01 Clinical and preclinical exploration of gene and cellular immunotherapy have seen rapid growth and interest with the development and approval of five Chimeric Antigen Receptor T-cell (CAR-T) products for lymphoma and myeloma and one Bispecific T-Cell Engager (BiTE) for acute lymphoblastic leukemia (ALL). These advances have dramatically improved the management of patients with relapsed refractory lymphoma, myeloma and leukemia. Gene and Cellular Immunotherapy for Cancer offers readers a comprehensive review of current cellular and gene-based immunotherapies. Divided into eighteen cohesive chapters, this book provides an in-depth and detailed look into cellular-based immunotherapies including CAR-T, TCR-T, TIL, Viral CTLs, NK cells in addition to T/NK cell engagers, focusing on their historical perspectives, biology, development and manufacturing, toxicities and more. Edited by two leading experts on gene and cellular immunotherapy, the book will feature chapters written by a diverse collection of recognized and up-and-coming experts and researchers in the field, providing oncologists, immunologists, researchers and clinical and basic science trainees with a bench to bedside view of the latest developments in the field. |
| aml car t therapy: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues World Health Organization, 2001 This is the third volume in the new World Health Organization series on histological and genetic typing of tumours. Tumours of the haematopoietic and lymphoid tissues are covered. This was a collaborative project of the European Association for Haematolpathology and the Society for Haematopathology and others. The WHO classification is based on the principles defined in the Revised European-American Classification of Lymphoid Neoplasms (REAL) classification. Over 50 pathologists from around the world were involved in the project and proponents of all major lymphoma and leukaemia classifications have agreed to accept the WHO as the standard classification of haematological malignancies. So this classification represents the first true world wide concensus of haematologic malignancies. Colour photographs, magnetic resonance and ultrasound images and CT scans are included. |
| aml car t therapy: Biology and Treatment of Leukemia and Bone Marrow Neoplasms Vinod Pullarkat, Guido Marcucci, 2021-10-09 This book provides a concise update on current understanding of the biology of acute and chronic leukemias and other bone marrow neoplasms, including myelodysplastic and myeloproliferative disorders, and explores new and emerging treatments. There is a particular focus on the molecular abnormalities that are drivers of leukemia and on their detection by modern molecular techniques. Knowledge of the ways in which genomic and metabolic abnormalities in the hematologic neoplasms affect prognosis and treatment decision making is reviewed. Detailed attention is devoted to targeted therapies, including novel drugs, and to potential targets for future drug development. In addition, readers find in-depth discussion of cellular and antibody-based immunotherapies as well as the role of hematopoietic stem cell transplantation in the treatment of leukemias and bone marrow malignancies. The book is of special interest for hematologists, oncologists, and cancer researchers; it is also of value for hematology trainees and medical students. |
| aml car t therapy: Minimal Residual Disease in Hematologic Malignancies Raanani P Ed, 2004 Detection of minimal residual disease (MRD) is increasingly used in the management of leukemia patients. A wide variety of methods have been developed and include technologies designed to detect residual malignant cells beyond the sensitivity of conventional approaches such as morphology and banding cytogenetics in leukemia. The choice of the best method depends on the biology of the individual malignancy, i.e. on the determination of specific markers which are useful to differentiate between leukemic cells and normal hematopoiesis in leukemic patients. These markers include leukocyte differentiation antigens, fusion transcripts, transcripts overexpressed by mutated or nonmutated genes, rearranged genes, and individual markers like polymorphic repetitive DNA sequences. The major technologies for MRD detection, their advantages and disadvantages and their clinical applications are discussed in this special issue - from 'bench to bedside'. Providing a comprehensive overview on the significance of MRD in the evaluation, treatment and follow-up of hematologic malignancies, it will be of great value to hematologists, researchers interested in leukemias and lymphomas as well as laboratory technicians. |
| aml car t therapy: Oncoimmunology Laurence Zitvogel, Guido Kroemer, 2017-12-13 In this book, leading experts in cancer immunotherapy join forces to provide a comprehensive guide that sets out the main principles of oncoimmunology and examines the latest advances and their implications for clinical practice, focusing in particular on drugs with FDA/EMA approvals and breakthrough status. The aim is to deliver a landmark educational tool that will serve as the definitive reference for MD and PhD students while also meeting the needs of established researchers and healthcare professionals. Immunotherapy-based approaches are now inducing long-lasting clinical responses across multiple histological types of neoplasia, in previously difficult-to-treat metastatic cancers. The future challenges for oncologists are to understand and exploit the cellular and molecular components of complex immune networks, to optimize combinatorial regimens, to avoid immune-related side effects, and to plan immunomonitoring studies for biomarker discovery. The editors hope that this book will guide future and established health professionals toward the effective application of cancer immunology and immunotherapy and contribute significantly to further progress in the field. |
| aml car t therapy: Childhood Cancer and Functional Impacts Across the Care Continuum National Academies of Sciences Engineering and Medicine, Health and Medicine Division, Board on Health Care Services, Committee on Childhood Cancers and Disability, 2021-09-09 Since the late 1960s, the survival rate in children and adolescents diagnosed with cancer has steadily improved, with a corresponding decline in the cancer-specific death rate. Although the improvements in survival are encouraging, they have come at the cost of acute, chronic, and late adverse effects precipitated by the toxicities associated with the individual or combined use of different types of treatment (e.g., surgery, radiation, chemotherapy). In some cases, the impairments resulting from cancer and its treatment are severe enough to qualify a child for U.S. Social Security Administration disability benefits. At the request of Social Security Administration, Childhood Cancer and Functional Impacts Across the Care Continuum provides current information and findings and conclusions regarding the diagnosis, treatment, and prognosis of selected childhood cancers, including different types of malignant solid tumors, and the effect of those cancers on childrenâ (TM)s health and functional capacity, including the relative levels of functional limitation typically associated with the cancers and their treatment. This report also provides a summary of selected treatments currently being studied in clinical trials and identifies any limitations on the availability of these treatments, such as whether treatments are available only in certain geographic areas. |
| aml car t therapy: Translational Research and Onco-Omics Applications in the Era of Cancer Personal Genomics Erika Ruiz-Garcia, Horacio Astudillo-de la Vega, 2019-11-11 Being a complex disease that affects millions of people world over, cancer research has assumed great significance. Translational cancer research transforms scientific discoveries in the laboratory into clinical application to reduce incidence of cancer, morbidity and mortality. On the other hand, personalized medicine in cancer is the concept that selection of a treatment should be tailored according to the individual patient’s specific genomic characteristics, including mutations, chromosomal aberrations, protein interactions, and SNPs, and even more, taking into account the inmume system, the metabolism and maybe in the next future also the microbiome. |
| aml car t therapy: Acute Leukemia Ashkan Emadi, MD, PhD, Judith E. Karp, MD, 2017-07-26 Acute Leukemia: An Illustrated Guide to Diagnosis and Treatment provides a comprehensive and concise visual reference on acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) seen in children and adults. This book addresses all aspects of AML and ALL including their risk factors, cytogenetics and mutational characteristics, diagnoses, clinical management and prognoses which are imperative and challenging for medical students, residents, hematology and medical oncology fellows, and even community oncologists and hematologists. It presents complex information relying predominantly on pictorial depictions rather than traditional text in a visually instructive format. It replaces the wordiness of a traditional textbook with original and adapted illustrations, instructive schemata and diagrams, photomicrographs, tables, detailed figure legends, and practical, ‘bite-sized’ text. The result is a visually engaging book that is easy to read, review, and remember. Crafted by world experts in the field, this digestible volume provides you with the must-know information that you can utilize when encountering AML and ALL patients who require immediate attention. Whether you are an early-career practitioner looking for quick guidance to managing a deadly disease or you are a seasoned clinician looking for a quick review of treatment protocols, this engaging format provides a unique and ‘go-to’ resource. Key Features: Contains over 40 tables and over 220 illustrations, histologic photomicrographs, flow diagrams, graphs, and schemata with detailed figure legends Presents complex scientific aspects such as cytogenetics and molecular mutations in a visually digestible and easy-to-understand format Provides helpful and evidence-based treatment recommendations when providing induction therapy, consolidation therapy, and bone marrow transplantation Includes unique chapters on managing psychosexual issues accompanying AML and ALL treatment as well as on the FDA drug development and clinical trial design process Includes digital access to the e-book as well as an online Image Bank |
| aml car t therapy: Immunopharmacogenomics Yusuke Nakamura, 2015-09-18 This book proposes immunogenomics, or immunopharmacogenomics, as the next-generation big science to uncover the role that the immune system plays in the pathogenesis of many diseases, by summarizing the importance of the deep sequencing of T-cell and B-cell receptors. Immunogenomics/immunopharmacogenomics, a genetic characterization of the immune system made possible by next-generation sequencing (NGS), will be important for the further understanding of the pathogenesis of various disease conditions. Abnormal immune responses in the body lead to development of autoimmune diseases and food allergies. Rejection of recipient cells and tissues, as well as severe immune reactions to donor cells, is also the result of uncontrolled immune responses in the recipient body. There have been many reports indicating that activated immune responses caused by the interaction of drugs and HLA are present in drug-induced skin hypersensitivity and liver toxicity. The importance of the host immune responses has been recognized in cancer treatments, not only for immunotherapy but also for cytotoxic agents and molecular targeted drugs. Hence, characterization of the T-cell receptor and B-cell receptor repertoire by means of NGS deep sequencing will ultimately make possible the identification of the molecular mechanisms that underlie various diseases and drug responses. In addition, this approach may contribute to the identification of antigens associated with the onset or progression of autoimmune diseases as well as food allergies. Although the germline alterations and somatic mutations have been extensively analyzed, changes or alterations of the immune responses during the course of various disease conditions or during various treatments have not been analyzed. It is also clear that computational analyses to draw meaningful inferences of functional recognition receptors on the immune cells remain a huge challenge. |
| aml car t therapy: Acute Myeloid Leukemia Juan M. Garza, 2015 Acute myeloid leukemia (AML) is an aggressive bone marrow cancer associated with high morbidity and mortality and most commonly affects older patient populations. In this book, the clinical presentation of acute myeloid leukemia are presented. Other chapters present the differences in the outcomes of two subtypes of core binding factor (CBF) acute myeloid leukemia (AML); examine the occurrence of the Philadelphia chromosome in AML with core binding factor leukemia; and therapeutic options of older patients with AML. |
| aml car t therapy: The European Blood and Marrow Transplantation Textbook for Nurses Michelle Kenyon, Aleksandra Babic, 2018-03-14 This book is open access under a CC BY 4.0 license. This textbook, endorsed by the European Society for Blood and Marrow Transplantation (EBMT), provides adult and paediatric nurses with a full and informative guide covering all aspects of transplant nursing, from basic principles to advanced concepts. It takes the reader on a journey through the history of transplant nursing, including essential and progressive elements to help nurses improve their knowledge and benefit the patient experience, as well as a comprehensive introduction to research and auditing methods. This new volume specifically intended for nurses, complements the ESH-EBMT reference title, a popular educational resource originally developed in 2003 for physicians to accompany an annual training course also serving as an educational tool in its own right. This title is designed to develop the knowledge of nurses in transplantation. It is the first book of its kind specifically targeted at nurses in this specialist field and acknowledges the valuable contribution that nursing makes in this area. This volume presents information that is essential for the education of nurses new to transplantation, while also offering a valuable resource for more experienced nurses who wish to update their knowledge. |
| aml car t therapy: Hematology Margarita Guenova, Gueorgui Balatzenko, 2018-06-27 Hematology has constantly been advancing in parallel with technological developments that have expanded our understanding of the phenotypic, genetic, and molecular complexity and extreme clinical and biological heterogeneity of blood diseases. This has in turn allowed for developing more effective and less toxic alternative therapeutic approaches directed against critical molecular pathways. The continuous and rather extensive influx of new information regarding the key features and underlying mechanisms as well as treatment options in hematology requires a frequent update of this topic. The primary objective of this book is to provide the specialists involved in the clinical management and experimental research in hematological diseases with comprehensive and concise information on some important theoretical and practical developments in the biology, clinical assessment, and treatment of patients, as well as on some molecular and pathogenetic mechanisms and the respective translation into novel therapies. |
| aml car t therapy: Bone Marrow Niche Takashi Nagasawa, 2021-12-01 This volume summarizes recent advances in research on mesenchymal cell populations in the bone marrow. It explores how mesenchymal cells create niches for immune cells in extramedullary organs and it discusses new concepts of lympho-hematopoietic microenvironments. Readers are introduced to the fundamentals of hematopoietic stem cells (HSCs) differentiation to all types of blood cells, including immune cells, in the bone marrow. The book highlights how this process is supported and regulated by the individual microenvironments of stem cells, termed niches. The identity of HSC niches has been subject to longstanding debates. Recent studies identified the population of mesenchymal stem cells as the major cellular component of niches, for hematopoietic stem and progenitor cells (HSPCs) and their candidate developmental origin. Furthermore, candidate cellular niches for immune cells in lymph nodes and adipose and connective tissues were identified. The authors of this volume focus on shared features between those and HSPC niche cells in the bone marrow. Covering latest research results, this book serves as fascinating read for researchers and clinicians in hematology and immunology. |
| aml car t therapy: Immunohistochemistry II A. Claudio Cuello, A. C. Cuello, 1993-07-20 Leading international experts describe both novel and established immunohistochemical techniques and interpret results and validity regarding the various methods used, particularly in the investigation of the nervous system. Coverage includes the immunocytochemistry (ICC) of second messenger molecules, applications of confocal microscopy to ICC, the latest pre-embedding and dual labeling EM techniques, anterograde PHAL tracing and more. |
| aml car t therapy: Surgical Pathophysiology A. Aasen, 1991-05-13 |
| aml car t therapy: CDC Yellow Book 2018: Health Information for International Travel Centers for Disease Control and Prevention CDC, 2017-04-17 THE ESSENTIAL WORK IN TRAVEL MEDICINE -- NOW COMPLETELY UPDATED FOR 2018 As unprecedented numbers of travelers cross international borders each day, the need for up-to-date, practical information about the health challenges posed by travel has never been greater. For both international travelers and the health professionals who care for them, the CDC Yellow Book 2018: Health Information for International Travel is the definitive guide to staying safe and healthy anywhere in the world. The fully revised and updated 2018 edition codifies the U.S. government's most current health guidelines and information for international travelers, including pretravel vaccine recommendations, destination-specific health advice, and easy-to-reference maps, tables, and charts. The 2018 Yellow Book also addresses the needs of specific types of travelers, with dedicated sections on: · Precautions for pregnant travelers, immunocompromised travelers, and travelers with disabilities · Special considerations for newly arrived adoptees, immigrants, and refugees · Practical tips for last-minute or resource-limited travelers · Advice for air crews, humanitarian workers, missionaries, and others who provide care and support overseas Authored by a team of the world's most esteemed travel medicine experts, the Yellow Book is an essential resource for travelers -- and the clinicians overseeing their care -- at home and abroad. |
| aml car t therapy: Successes and Challenges of NK Immunotherapy Benjamin Bonavida, Anahid Jewett, 2021-06-23 Successes and Challenges of NK Immunotherapy: Increasing Anti-tumor Efficacy describes the unique therapeutic applications of NK cells to fight cancers and eliminate the bulk and subset of cancer stem cells responsible for metastasis, relapse and recurrences. The book provides information on the development, engineering, mechanisms of action, response to various preclinical models, and applications in various clinical trials. Sections cover the development of highly engineered cytotoxic NK cells, their mechanisms of action, preclinical and clinical applications, the development and application of CAR-NK cells, and new NK-drug conjugates, also emphasizing that activated NK cells can target and kill highly resistant cancer stem cells. Written by the leading experts on NK immunotherapy worldwide, this is a valuable resource for researchers, clinicians and members of the biomedical field who are interested in understanding novel and efficient therapies to fight cancers. - Discusses the unique developmental applications of NK immunotherapy against cancers, which differs greatly from other types of immunotherapies - Provides up-to-date and highly relevant information through chapters written by the leading researchers in the field - Presents a significant number of schematic diagrams for easy understanding and reproducibility |
| aml car t therapy: Advances in Allogeneic Hematopoietic Stem Cell Transplantation Richard K. Burt, Mary M. Brush, 2000-02-29 The field of hematopoietic stem cell transplantation is rapidly evolving. Realization that hematopoietic stem cells give rise to the immune compartment has resulted in clinical trials of hematopoietic stem cell transplantation for patients with autoimmune diseases. Allogeneic hematopoietic transplants are a form of adoptive immunotherapy resulting in beneficial graft versus tumor effects. Large numbers of hematopoietic cells can be collected with ease. Therefore, a renewable source of cells for ex vivo genetic manipulations is readily available. Multiple trials combining hematopoietic transplants and gene therapy are in progress. One such application is the infusion of allogeneic lymphocytes containing a suicide gene to abort graft versus host disease. Hematopoietic stem cell transplantation is in reality the clinical and practical application of cellular therapy. Hematopoietic transplant physicians are by design or by practical application evolving into cell and gene therapy specialists. The excitement and enthusiasm in hematopoietic transplantation is that it offers a door to the future. A future not of drugs or titrating poisonous chemotherapy but rather of cellular and gene therapy. 1 ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FOR HEMATOLOGIC DISEASES Martin Korbling University o/Texas MD. Anderson Cancer Center, Houston, Texas 77030 INTRODUCTION Circulating hematopoietic stem cells have emerged as an alternative to bone marrow (BM) stem cells for allografting. For many years the reconstitutive potential of circulating stem cells was questioned; peripheral blood stem cells (PBSC) were even characterized a waste product (1). |
| aml car t therapy: Brain Tumor Imaging Elke Hattingen, Ulrich Pilatus, 2015-09-02 This book describes the basics, the challenges and the limitations of state of the art brain tumor imaging and examines in detail its impact on diagnosis and treatment monitoring. It opens with an introduction to the clinically relevant physical principles of brain imaging. Since MR methodology plays a crucial role in brain imaging, the fundamental aspects of MR spectroscopy, MR perfusion and diffusion-weighted MR methods are described, focusing on the specific demands of brain tumor imaging. The potential and the limits of new imaging methodology are carefully addressed and compared to conventional MR imaging. In the main part of the book, the most important imaging criteria for the differential diagnosis of solid and necrotic brain tumors are delineated and illustrated in examples. A closing section is devoted to the use of MR methods for the monitoring of brain tumor therapy. The book is intended for radiologists, neurologists, neurosurgeons, oncologists and other scientists in the biomedical field with an interest in neuro-oncology. |
| aml car t therapy: Cell and Gene Therapies Miguel-Angel Perales, Syed A. Abutalib, Catherine Bollard, 2018-11-27 In this book, experts in the field express their well-reasoned opinions on a range of complex, clinically relevant issues across the full spectrum of cell and gene therapies with the aim of providing trainee and practicing hematologists, including hematopoietic transplant physicians, with information that is relevant to clinical practice and ongoing research. Each chapter focuses on a particular topic, and the concise text is supported by numerous working tables, algorithms, and figures. Whenever appropriate, guidance is provided regarding the availability of potentially high-impact clinical trials. The rapid evolution of cell and gene therapies is giving rise to numerous controversies that need to be carefully addressed. In meeting this challenge, this book will appeal to all residents, fellows, and faculty members responsible for the care of hematopoietic cell transplant patients. It will also offer a robust, engaging tool to aid vital activities in the daily work of every hematology and oncology trainee. |
| aml car t therapy: Natural Killer Cells Srinivas S. Somanchi, 2016-05-13 This volume contains collection of Natural Killer Cell methodologies relevant for both basic and translational research. These methodologies present new developments in the natural killer (NK) cell field, such as understanding the influence of NK cells metabolism on its function, identifying complexity of NK cell subsets through mass cytometry, and determining the emergence of memory NK cells in murine model of MCMV infection. Methods that study NK cell migration and cytotoxicity through endpoint analysis or live single cell imaging are also discussed. Chapters also describe methods pertaining to translational application of NK cells, such as ex vivo expansion of NK cells on K562 cell lines genetically modified to express either membrane bound IL-15 or membrane bound IL-21, large scale NK cell culture, current techniques for engineering NK cells to express chimeric antigen receptors or chemokine receptors using retroviral vectors, electroporation of mRNA, and the natural phenomenon of trogocytosis. Written in the highly successful Methods in Molecular Biology series format, these chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Cutting edge and thorough, Natural Killer Cells: Methods and Protocols is a valuable resource for researchers who not only want to understand mechanisms that govern NK cell behavior and diversity, but also for those who want to understand how to systematically evaluate NK cells for adoptive immunotherapy applications. |
| aml car t therapy: Six Years and Counting Peter Gordon, 2017-09-12 A bone marrow transplant and beyond: an American healthcare odyssey... Having rebuilt his life after a painful divorce, Peter was on top of the world. Recently remarried, a thriving career, living in a beautiful mountain resort - life was looking up again. Suddenly an aggressive case of leukemia turned his world upside down. His only hope for survival was a bone marrow transplant, and at his age the outlook wasn't good... In this gripping chronicle, Peter Gordon describes the initial shock, the ensuing scramble, the anxious wait for a matching donor, the long hospitalization for the transplant itself, and the surprisingly difficult road afterward. And that's just part of the story. His wife suffers a debilitating injury, tossing the couple into intertwined roles of patient and caregiver. For several years they struggle together through one challenge after another. Peter's story provides a riveting, in the moment view of a regular guy and his wife grappling with cancer and its many offshoots. He shares razor-sharp observations, moments of deep introspection, and the wide emotional swings of their journey: from stressful and gut-wrenching, to humorous, heartwarming, and poignant. Six Years and Counting is a real-world healthcare saga for our times, offering insightful lessons for cancer patients, caregivers, and medical professionals. It's also a touching story about relationships, family, and self-discovery - and ultimately an inspiring tale of resilience and love. |
| aml car t therapy: Stem Cell Transplantation for Hematologic Malignancies Robert J. Soiffer, 2004 A comprehensive survey of the current state-of-the-art in hematopoietic stem cell transplantation for malignant disease. The authors focus on the indications and results of transplantation for acute leukemia, chronic myelogenous leukemia, lymphoma, multiple myeloma, and breast cancer. Special attention is given to transplant-related complications, including the pathophysiology and clinical consequences of acute and chronic GVHD, delayed immune reconstitution leading to infectious complications, and organ damage to the lung and liver. Additional chapters address the sources of stem cells and the effects of graft manipulation used to eliminate residual contaminating tumor cells in autologous transplantation, or to reduce the number of T lymphocytes causing GVHD in allogenic transplantation. |
| aml car t therapy: Cancer Immunotherapy Principles and Practice Lisa H. Butterfield, Howard L. Kaufman, Francesco M. Marincola, 2017 Part 1: Intratumoral Signatures Associated With Immune Responsiveness |
| aml car t therapy: Hematology Ronald Hoffman, 2005 |
| aml car t therapy: CAR T-Cell, An Issue of Hematology/Oncology Clinics of North America, E-Book Caron A Jacobson, Parth S. Shah, 2023-10-12 In this issue of Hematology/Oncology Clinics, guest editors Drs. Caron A. Jacobson and Parth S. Shah bring their considerable expertise to the topic of CAR T-Cell Therapy. Top experts in the field discuss the multiple ways CAR T-cell therapy can be used to help fight a variety of cancers, such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukemia (ALL). - Contains 12 practice-oriented topics including CAR T-cells in aggressive B-cell lymphomas; CAR T-cells in multiple myeloma; CAR T-cells in AML; mechanisms of resistance of CAR T-cell therapy; the role of CAR T-cell therapy in the era of bispecific antibodies; and more. - Provides in-depth clinical reviews on CAR T-cell therapy, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews. |
| aml car t therapy: Adaptive Immune Resistance in Cancer Therapy Lin Qi, Zhigang Liu, Ouyang Chen, Hongzhou Cai, 2024-02-16 The adaptive immune resistance (AIR) mechanism refers to the various strategies employed by tumours to adapt and ultimately to overcome immune attack. The AIR mechanism was firstly identified in the selective induction of programmed cell death 1 ligand 1 (PDL1) by interferon gamma of tumors. The inhibition of adaptive immune resistance underlies the responses to PD-1 or PD-L1–blocking antibodies, and may have relevance for the development of other cancer immunotherapy strategies. Therefore, identifying specific AIR mechanisms is of great significance to develop novel drugs and enhance the efficacy of cancer treatment. In this research topic, we aim to generate a collection of articles that discuss the AIR mechanisms, the classification of AIRs, and the current and future cancer therapy strategies based on AIR. Of particular, these articles can focus on exploring the AIR mechanisms in different cancer types and further identify the association between AIR and tumour microenvironment (TME). |
| aml car t therapy: Immunotherapies for Acute Myeloid Leukemia Jochen Greiner, 2020-12-02 The efficacy of immunotherapeutic approaches in the treatment of different cancer types is becoming increasingly obvious, and immunotherapies in cancer treatment have experienced a significant breakthrough in the last few years. Immunotherapy encompasses several diverse treatment approaches, each of which has a distinct mechanism of action, and all of which are designed to boost or restore immune function in some manner. Consequently, T cell activating immunotherapeutic approaches like immune checkpoint inhibition, chimeric antigen receptor T cells (CARs), or bi-specific T cell activating antibodies are becoming increasingly important treatment strategies in different solid tumor types as well as in hematological malignancies. T cell responses against malignant cells play a major role in maintaining remission and prolonging overall survival in patients after allogeneic stem cell transplantation and donor lymphocyte infusions (DLI) due to the graft-versus-leukemia effect. In acute myeloid leukemia (AML) after intensive chemotherapy, most patients achieve complete remission; however, the overall survival for all AML patients, especially in elderly patients, is still relatively low. Immunotherapeutic approaches for AML patients might be options to reduce the relapse rate and improve overall survival. This Special Issue will focus on immunotherapeutic approaches in AML in established therapies, like the allogeneic stem cell transplantation including new concepts improving the graft-versus-leukemia effect, but also on new efforts to improve immune responses like adoptive T cell transfer, immune checkpoint inhibition, bi-specific antibodies, and CAR-T-cell approaches. |
| aml car t therapy: Innovations in Development, Translational Research and Manufacturing of CAR T cells Michael Hudecek, Qasim Rafiq, Stephen Goldrick, Ulrike Koehl, Helene Negre, Carmen Sanges, 2024-10-03 Immunotherapy with genetically engineered immune cell products is a transformative treatment modality with potential applications in various fields of medicine. A prime example is chimeric antigen receptor (CAR)-modified T cells in hematology and oncology, and the advent of CAR T cell therapies to treat infectious diseases, autoimmune disorders, and cardiovascular diseases. The medical need and demand from patients and caregivers require radical innovations to accelerate and improve pre-clinical development and clinical translation, provision of gene-transfer vectors, and immune cell product manufacturing as well as a critical reflection and discussion on ethical and socioeconomic aspects. The goal of this special issue of Frontiers in Immunology is to provide a comprehensive and multi-faceted view on the current state-of-the-art, imminent and future directions the field is taking in order to accelerate the pre-clinical development, clinical translation, and manufacturing of CAR T cells, increase access and sustainability of CAR T cell therapy for health care systems (in developed and in developing countries). This special issue will focus on the medical and scientific dimension incl. approved and emerging indications, new areas in medicine, advanced gene-transfer and gene-editing technologies, innovations in pre-clinical assessment (efficacy, toxicology, genomic safety), innovations in scalable automated manufacturing (bioprocessing), the implementation of high content data acquisition, machine learning and artificial intelligence, innovations in clinical trial design; and consider the ethical, socioeconomic and societal dimension of CAR T cells in particular and gene-engineered immune cell therapy in general. |
Acute myelogenous leukemia - Symptoms and causes - Ma…
Dec 20, 2024 · Acute myelogenous leukemia, also called AML, is a cancer of the blood and bone marrow. Bone marrow is the soft matter inside …
Acute Myeloid Leukemia (AML) - Cleveland Clinic
Acute myeloid leukemia (AML) is a rare cancer that affects your bone marrow and blood. AML typically affects people age 65 and older, but it can affect …
What Is Acute Myeloid Leukemia (AML)? - American …
Acute myeloid leukemia (AML) has many other names, including acute myelocytic leukemia, acute myelogenous leukemia, acute …
Acute myeloid leukemia - Wikipedia
Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal cells that build up in …
Acute Myeloid Leukemia (AML): Symptoms, Treatment …
Nov 27, 2024 · Acute myeloid leukemia (AML) is a type of blood cancer.Learn about this cancer that forms in the bone and bone marrow. Treatments …
Bone Marrow Transplant and Cellular Therapy Program
outcomes (e.g., relapse prevention studies in FLT3 AML patients) for our patients. CAR-T therapy Rush offers CAR-T cell therapy for patients who have relapsed refractory lymphoma or acute …
What to Do When Cancer Comes Back After Transplant or …
CAR T-cell therapy . treats relapse after auto- or Allo-transplant • Immune-checkpoint blockade therapy . has been used with relapse after allo-BMT, but it may cause GvHD • Hypomethylating …
CD7 CAR T Cells for the Therapy of Acute Myeloid …
Original Article CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia Diogo Gomes-Silva, 1,2 Erden Atilla, Pinar Ataca Atilla, 1Feiyan Mo, 3 Haruko Tashiro, Madhuwanti Srinivasan, …
Developing a Dual-Targeting Anti-CD70/Active Integrin β2 …
Integrin β2 CAR-T Therapy for Acute Myeloid Leukemia National Academies Workshop on Cancer Engineering Amrik Kang. ... Blood Cancer Journal 2021. Major Challenges for AML …
CAR-T Therapy - ECPC
CAR-T therapy is not yet reimbursed in every MS, which is an added barrier to cross-border patient access. Thus, cross-border access, be it regional, national or between insurers, could …
Anti-CD117 CAR T cells incorporating a safety switch …
Original Article Anti-CD117 CAR T cells incorporating a safety switch eradicate human acute myeloid leukemia and hematopoietic stem cells Chiara F. Magnani, 1Renier Myburgh, Silvan …
Abstracts / Transplantation and Cellular Therapy 30 2S (2024) …
Challenges for autologous AML CAR T cell therapy include inade-quate numbers of functional, undifferentiated T cells in the start-ing material, and the potential presence of AML blasts that …
CD7 CAR-T therapy for an AML patient with CD7 expression
potential effects of CAR-T therapy against AML by tar-geting antigens such as CD123, CD44v6, Lewis Y, FLT3, CLL-1 or CD19 in patients with AML with CD19 expres-sion [5-7].
Selective homing of CAR-CIK cells to the bone marrow niche …
3 Introduction The therapeutic potential of chimeric antigen receptor (CAR)-T cells for patients suffering from acute myeloid leukemia (AML) is still far from being realized due to multiple …
Siglec6 CAR T cells suppressed progression of AML via …
To explore the specific molecular mechanisms of Siglec6 CAR-T therapy in acute myeloid leukemia (AML). AML samples were selected from the GEO database for bioinformatics …
Targeting the mevalonate or Wnt pathways to overcome CAR …
Feb 14, 2024 · In vitro rational targeting of either of these pathways rescues AML cell sensitivity to CAR T-cell-mediated killing. We thus demon-strate that TP53 deficiency confers resistance to …
Chimeric antigen receptor T cell therapies for acute myeloid
data on the effectiveness of an anti-CD33 CAR T therapy for AML in mice and support its development as a clinical therapeutic approach [23,24]. Considering the potential toxicity …
CD7-directed CAR T-cell therapy: a potential immunotherapy …
rst case of r/r AML successfully treated with CD7 CAR T-cell therapy. e result suggests that CD7 CAR T-cell therapy is an encouraging approach for the treatment of CD7 positive r/r AML. …
Persistence and Efficacy of Second Generation CAR T Cell …
CAR T cells infiltrated proven sites of disease. Serial PCR of PB and BM for the LeY transgene demonstrated that infused CAR T cells persisted for up to 10 months. Our study supports the …
Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute …
disease. CD19-targeting therapies employing chimeric antigen receptor (CAR) T cells are a breakthrough in cancer therapy. A similar approach for myeloid malignancies is highly …
Original Article Successful application of PD-1 knockdown CLL …
ic targets of CAR-T cells, such as Lewis Y, CD33, CD123 and CD38, have been explored in pre-clinical studies and a few clinical trials. However, there are still various difficulties for CAR-T …
Car T Therapy For Aml - tournaments.gamblingnews.com
Sep 25, 2023 · Car T Therapy For Aml Susan O'Brien,Julie M. Vose,Hagop M. Kantarjian Fast Facts: CAR T-Cell Therapy R.J. Buka,A.J. Kansagra,2021-01-26 Chimeric antigen receptor …
Investigation of ALLO-316: A Fratricide-Resistant Allogeneic …
Resistant Allogeneic CAR T Targeting CD70 As a Potential Therapy for the Treatment of AML Surabhi Srinivasan, Nguyen Tan, Hsin-Yuan Cheng, Yi Zhang, Silvia Tacheva-Grigorova, Tom …
Valproic acid increases CAR T cell cytotoxicity against acute …
conclusion, CD123 and CLL-1 are promising targets for AML CAR-T cell therapy. A combination of VPA pre- treatment and CAR-T against AML exhibits synergic effects. BACKGROUND In …
Car T Therapy For Aml - tournaments.gamblingnews.com
Car T Therapy For Aml William J. Brock,Kenneth L. Hastings,Kathy M. McGown Fast Facts: CAR T-Cell Therapy R.J. Buka,A.J. Kansagra,2021-01-26 Chimeric antigen receptor (CAR) T cells …
Off-the-Shelf CAR-NK Cell Therapy Elicits Leukemia Remission
Several patients with acute myeloid leukemia (AML), who were treated with SENTI-202, a first-in-class chimeric antigen receptor natural killer (CAR NK) cell therapy, experienced a complete ...
B7-H3-Targeted CAR-T Cells Exhibit Potent Antitumor Effects …
tients with acute myeloid leukemia (AML) was 57.2% (range 38.8–80.4). Furthermore, we showed that the B7-H3-tar-geted CAR-T cells exhibited significant antitumor activity against AML and …
ALLO-819, AN ALLOGENEIC FLT3 CAR T THERAPY …
This work details the preclinical evaluation of ALLO-819, an allogeneic CAR T therapy targeting the receptor tyrosine kinase FLT3 (CD135), an AML target with high prevalence in all AML …
Targets for chimeric antigen receptor T-cell therapy of
CAR T-cell therapy for AML, CD123 is currently the most Schorr and Perna 10.3389/fimmu.2022.1085978 Frontiers in Immunology 02 frontiersin.org. TABLE 1 …
CAR T cell therapy of AML and ALL: A mini review - JCIMCR
Citation: Moeini O, Hosseini A, Rahmani A, Nourikhani M. CAR T cell therapy of AML and ALL: A mini review. J Clin Images Med Case Rep. 2023; 4(4): 2367. agents such as fludarabine, …
CD37 is a safe chimeric antigen receptor target to treat acute …
We repurpose the anti-lymphoma CD37CAR for the treatment of AML and show that CD37CAR T cells spe-cifically kill AML cells, secrete proinflammatory cytokines, and control cancer …
CAR'TCR-T cells co-expressing CD33-CAR and dNPM1-TCR as …
Original Article CAR’TCR-T cells co-expressing CD33-CAR and dNPM1-TCR as superior dual-targeting approach for AML treatment Karin Teppert, 1,5Isabella Elias Yonezawa Ogusuku, …
Chimeric antigen receptor T cell therapies for acute myeloid
ideal target antigen for AML is challenging, CAR T therapy remains a highly promising strategy for AML patients, particularly for those who are ineligible to receive a transplantation or have …
Optimization of universal allogeneic CAR-T cells combining
cell numbers, suboptimal CAR-T cell functions, and unsuccessful CAR-T cell production (8). However, there is a lack of studies performing a detailed and deep characterization of AML …
Targeting CD117 on hematopoietic stem and progenitor cells …
CAR T cell activity Rubina Thomas,1 Julie K. Ritchey, 1John F. DiPersio, and Miriam Y. Kim1 1Department of Medicine, Division ... matopoietic stem cell transplantation and a therapy for …
Exploiting HLA-DR mismatches for CAR therapy in acute …
for CAR therapy for AML, most are also expressed on normal cells, increasing the risk of on-target, off-tumor toxicity. ... Residual AML cells (recipient derived) KG2032 CAR T cell or CAR …
Novel CAR T therapy is a ray of hope in the treatment of …
the commonly used CAR T cells which has exhibited strong and long-lasting anti-tumor activity in acute lymphocytic leukemia (ALL). It is the first CAR T cell approved by U.S. FDA [14]. In this …
CAR-NK cell therapy for hematological malignancies: recent …
multiple myeloma. This correspondence summarizes the preclinical and clinical updates for universal CAR-NK cell therapy reported at the ASH 2022 annual meeting. Keywords CAR NK …
Safety and efficacy of CD33-targeted CAR- NK cell therapy
cies [1–4], and several CD19 CAR-T-cell therapies have been approved by drug administration facilities world-wide [1]. However, clinical trials related to CAR-T-cell therapies for R/R AML …
IMMUNOBIOLOGY AND IMMUNOTHERAPY Bispeci c and split …
Plenary Paper IMMUNOBIOLOGY AND IMMUNOTHERAPY Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia Xin He, 1,* Zijie Feng, * Jian Ma, …
Bispecific CD33/CD123 targeted chimeric antigen receptor T …
ceptor (CAR) T cell therapies.12,13 CAR T cell therapy has shown significant potential as a cancer therapy.14,15 CAR T cells have demonstrated remarkable activity for treating …
Targets for chimeric antigen receptor T-cell therapy of acute …
approval for CAR T-cell therapy in AML thus far. CARs are synthetic receptors that retarget and reprogram T cells (2). Unlike the physiological T-cell receptor, which engages HLA-peptide …
CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia
Original Article CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia Diogo Gomes-Silva, 1,2 Erden Atilla, Pinar Ataca Atilla, 1Feiyan Mo, 3 Haruko Tashiro, Madhuwanti Srinivasan, …
The EBMT/EHA CAR-T Cell Handbook
Chimeric antigen receptor T cell therapy (CAR-T) is a new class of medicinal prod-ucts that are genetically engineered from T cells. It is expected that other forms of Immune Effector Cells …
Chimeric antigen receptors for adoptive T cell therapy in
CAR T cell therapy in AML and summarize the strat-egies of building CAR T cells with improved safety and availability. The application of CAR-modified T cells in AML Despite the enormous …
Safety and efficacy of CD33-targeted CAR- NK cell therapy …
cies [1–4], and several CD19 CAR-T-cell therapies have been approved by drug administration facilities world-wide [1]. However, clinical trials related to CAR-T-cell therapies for R/R AML …
Preclinical evaluation of CB-012, an allogeneic anti-CLL-1 CAR …
first-in-human clinical trial for patients with r/r AML (NCT06128044). •CLL-1 is a compelling therapeutic target for AML as it is highly expressed on AML tumor cells and leukemic stem …
CAR-T療法の現状と今後の展望 - 大学病院医療情報 ...
car-t 療法 2010年以降，cd19抗原陽性造血器腫瘍に対する cd19 car-t療法の臨床試験の結果が米国国立がん 研究所（nci）7）8），ペンシルバニア大学（upenn）9）10）， スローン・ケタ …
Safety and efficacy of CD33-targeted CAR- NK cell therapy …
One potential challenge in applying CAR-T-cell therapy to AML is the limited availability of suitable targets for malignant myeloid cells. The targets for AML treatment
Car T Therapy Aml (Download Only) - old.icapgen.org
Car T Therapy Aml: The EBMT/EHA CAR-T Cell Handbook Nicolaus Kröger,John Gribben,Christian Chabannon,Ibrahim Yakoub-Agha,Hermann Einsele,2022-02-07 This first …
Integrated scFv identification and CAR T cell generation for …
Oct 8, 2024 · original antibody and have versatile applications in cancer therapy, including monoclonal antibody 95 development, targeted drug delivery, and CAR T cell therapy3-8. FDA …
CAR T cells redirected to cell surface GRP78 display robust
served across species15, is a promising target for AML-redirected CAR T cell therapy since it normally resides in the endoplasmic reticulum (ER)16. GRP78 contains a C-terminal KDEL …
Novel CAR T therapy is a ray of hope in the treatment of …
REVIEW Open Access Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients Faroogh Marofi1, Heshu Sulaiman Rahman2,3, Zaid Mahdi Jaber Al-Obaidi4,5, …
Discovery and preclinical development of a SdAb-based CAR …
Original Article Discovery and preclinical development of a SdAb-based CAR-T technology for targeting CD33 in AML Franco Bernasconi-Bisio, 1Eva Molina, Vianca Ibarra, 1Inés Ibáñez …
IL-21/IL-21R signaling renders acute myeloid leukemia stem
Nov 12, 2024 · Article IL-21/IL-21R signaling renders acute myeloid leukemia stem cells more susceptible to cytarabine treatment and CAR T cell therapy Viviana Rubino,1,2,3 Michelle …
